The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

1 Jul 2013 09:41

RNS Number : 2542I
Akers Biosciences, Inc.
01 July 2013
 



 

1 July 2013

 

 

Akers Biosciences, Inc.

 

("ABI" or the "Company")

 

Appointment of Non-Executive Directors

 

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

 

Mr Moran, aged 43, is an Irish national who has previously worked for Shell International in Shell Chemicals, Marketing, Finance and Shell International Trading. He then held a Trading role as a beneficial shareholder at Trafigura, a leading international commodities trading and logistics company based in Amsterdam and then a Trading role as a beneficial shareholder at Sono International based in London. Mr Moran is indirectly interested through Chubeworkx Guernsey Limited, in which he holds a 31.69 per cent. shareholding, 80 million common shares in the Company, which represents 28.70 per cent of the Company's shares and 24.30 per cent. of the Company's voting rights.

 

Mr Knox, aged 72, is a Philadelphia, Pennsylvania-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He currently holds 30 million common shares and 10 million preference shares, which represents 10.76 per cent of the Company's shares and 28.78 per cent. of the Company's voting rights.

 

Raymond F. Akers, Executive Chairman of ABI commented, "It gives me great pleasure to welcome Gavin and Thomas to our Board. They have both invested in the company in the past year and bring with them expertise and experience, which will help move the company forward in the future. My colleagues and I are very much looking forward to our working together."

Further information concerning Mr Moran

Gavin Edwin David Moran's directorships (current and within the previous 5 years) are as follows:

 

Current: None

 

Past: None

 

Further information concerning Mr Knox

 

Thomas James Knox, a Chartered Life Underwriter (CLU) and Chartered Financial Consultant (ChFC), has been involved in Philadelphia politics having held the position of Deputy Mayor for the Office of Management and Productivity. Mr Knox is the Chief Executive Officer of Knox Consulting Group, Knox Family Loan Company and INDECS Corp.

Thomas James Knox's directorships (current and within the previous 5 years) are as follows:

 

Current: Knox Consulting Group

Knox Family Loan Company

INDECS Corp

Historic Philadelphia, Inc.

Newman Wine and Spirit Company

ORB Automotive based in Shenzhen, China

 

Past: None

 

There is no further information required relating to Thomas J. Knox or Gavin E.D. Moran to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

 

 

 

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

End

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVFLBBXDFXBBK
Date   Source Headline
14th Jul 20177:00 amRNSNotice of AGM & Directorate Changes
3rd Jul 20172:53 pmRNSForm S-3 Registration Statement
9th Jun 20174:51 pmRNSIssue of Equity
16th May 20177:00 amRNS1st Quarter Results
12th May 20172:30 pmRNSNotice of Q1 Results
5th May 201710:53 amRNSIssue of Equity
24th Apr 20175:12 pmRNSIssue of Equity
11th Apr 20179:13 amRNSHolding(s) in Company
11th Apr 20177:00 amRNSFinal Results
10th Apr 20173:00 pmRNSNotice of Results
10th Apr 201712:00 pmRNSIssue of Equity
10th Apr 20177:00 amRNSHeparin PF4 Rapid Test in Puerto Rico
6th Apr 20175:39 pmRNSIssue of Equity
4th Apr 20174:18 pmRNSIssue of Equity
31st Mar 20177:00 amRNSIssue of Equity
30th Mar 20171:30 pmRNSDetailed Year-end Trading Update
29th Mar 20177:00 amRNSNotice of Results
28th Mar 201712:00 pmRNSInitial Order for Rapid Cholesterol Self-test
16th Feb 20177:00 amRNSUS Patent for Akers Wellness Tests Cartridge
1st Feb 20177:00 amRNSTrading Update
13th Jan 20177:00 amRNSIssue of Equity
10th Jan 20177:00 amRNSIssue of Equity
9th Jan 20177:00 amRNSSupplement to Form S-3 Registration Statement
19th Dec 20165:00 pmRNSResult of AGM
19th Dec 20167:00 amRNSAgreement with GNYHA for PIFA Heparin PF4 Test
1st Dec 201612:00 pmRNSUS Distribution Agreement: Cholesterol Self-test
28th Nov 20167:06 amRNSClinical Trial for BreathScan DKA Completed
17th Nov 20167:00 amRNSSupplement to Form S-3 Registration Statement
14th Nov 201612:00 pmRNSNotice of AGM
14th Nov 20167:00 amRNS3rd Quarter Results
10th Nov 20167:00 amRNSEuropean Patent Granted
9th Nov 20164:29 pmRNSNotice of Q3 Results
25th Oct 20167:00 amRNSFiling of Form S-3 Registration Statement
19th Aug 20167:00 amRNSSettlement of Dispute with ChubeWorkx
18th Aug 20167:00 amRNSResults of OxiChek Test Study
11th Aug 20167:00 amRNSHalf Yearly Results
9th Aug 20164:00 pmRNSNotice of H1 2016 Earnings
30th Jun 20167:00 amRNSClinical Trial for Rapid Chlamydia Test Completed
27th Jun 20167:00 amRNSDistribution Agreement for BreathScan OxiChekT
14th Jun 201612:00 pmRNSIssue of Equity & PDMR Shareholding
26th May 20165:10 pmRNSPDMR Shareholding
12th May 20167:00 amRNSFinancial Results for Q1 2016
10th May 201612:00 pmRNSNotice of Q1 Results
25th Apr 201612:00 pmRNSBoard Rearrangement
30th Mar 20167:00 amRNSFinal Results
23rd Mar 20167:00 amRNSUS Patent - Heparin/PF4 Antibody Detection
16th Mar 20167:00 amRNSNotice of Results
2nd Mar 20167:00 amRNS$2.5M Product Order
29th Feb 20167:00 amRNSSenior Commercial Team Appointments
6th Jan 20167:00 amRNSDirectors Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.